Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Gemcitabine is the first-line treatment for pancreatic adenocarcinoma, but is increasingly
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …

Pancreatic cancer is a lethal disease with limited opportunity for resectable surgery as the
first choice for cure due to its late diagnosis and early metastasis. The desmoplastic stroma …

Gemcitabine (2′, 2′-difluoro 2′-deoxycytidine, dFdC) is the most important cytidine
analogue developed since cytosine arabinoside (Ara-C). The evidence of its potent …

Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The
disappointing 5-year survival rate of below 5% stems from drug resistance to all known …

Gemcitabine is an antimetabolite ranking among the most prescribed anticancer drugs
worldwide. This nucleoside analog exerts its antiproliferative action after tumoral conversion …

Pancreatic ductal adenocarcinoma (PDAC) has a devastating prognosis without effective
treatment options. Thus, there is an urgent need for more effective and safe therapies. Here …

Effective development of targeted anticancer agents includes the definition of the optimal
biological dose and biomarkers of drug activity. Currently available preclinical models are …

Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new
cytotoxic agents. The drug has shown activity in a variety of solid tumors, and has been …

Despite advances in breast cancer treatments and related 5-year survival outcomes,
metastatic breast cancer cures remain elusive. The current standard of care includes a …